Moderna, Inc. $MRNA Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 33.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,836 shares of the company’s stock after selling 57,850 shares during the quarter. Voya Investment Management LLC’s holdings in Moderna were worth $2,915,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC increased its position in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares during the period. Atlantic Union Bankshares Corp acquired a new stake in shares of Moderna in the second quarter valued at about $26,000. TD Private Client Wealth LLC boosted its holdings in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in Moderna during the second quarter worth about $28,000. Finally, Whittier Trust Co. acquired a new position in Moderna during the second quarter worth about $28,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $31.20 on Friday. The business’s fifty day moving average price is $27.00 and its two-hundred day moving average price is $27.39. The stock has a market cap of $12.19 billion, a PE ratio of -3.87 and a beta of 1.11. Moderna, Inc. has a one year low of $22.28 and a one year high of $48.92.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business’s revenue was down 45.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 earnings per share. As a group, equities research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MRNA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a research note on Monday, December 1st. Citigroup decreased their target price on Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Bank of America lowered their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $17.00 price target on shares of Moderna in a research note on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Reduce” and an average target price of $29.21.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the transaction, the director directly owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.90% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.